Levosynt

Carbidopa/Levodopa, the active ingredient in Levosynt, is an antiparkinson agent presented as an oral tablet formulation for oral use. It is prescribed to manage motor symptoms in patients with Parkinson's disease and related Parkinsonian syndromes.

GNH USA supplies Levosynt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides regulatory documentation for import and distribution. Levosynt is manufactured in the European Union and exported under strict quality‑assurance protocols.

Levosynt (carbidopa/levodopa) is used in the management of Parkinsonian disorders that affect dopaminergic pathways.

- Parkinson's disease: improves motor function and reduces rigidity, tremor, and bradykinesia. - Parkinsonian syndrome: alleviates symptoms in secondary Parkinsonism and drug‑induced parkinsonism. - Levodopa‑responsive Parkinsonism: provides symptomatic relief in patients who respond to dopaminergic therapy.

Levosynt may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: feeling of stomach upset, often occurring after the first doses. - Vomiting: expulsion of stomach contents, may accompany nausea. - Orthostatic hypotension: drop in blood pressure upon standing, leading to dizziness. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Dyskinesia: involuntary, erratic movements that can be disabling. - Hallucinations: visual or auditory perceptions without external stimulus. - Severe hypotension: marked blood pressure drop causing fainting. - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever, rigidity, and autonomic instability.

When prescribing Levosynt, clinicians should observe several precautionary measures to ensure safe use.

- Dose titration: start with a low dose and increase gradually to minimize side effects. - Monitor for dyskinesia: watch for involuntary movements that may develop with chronic therapy. - Assess renal and hepatic function: adjust dosing in patients with impaired organ function. - Avoid abrupt discontinuation: taper the medication to prevent withdrawal and worsening of symptoms. - Pregnancy and lactation: use only if potential benefit justifies potential risk to the fetus or infant. - Store at ambient temperature: keep tablets in the original container, protect from moisture and heat.

Levosynt can interact with several medicines, requiring careful management to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Non‑selective MAO‑B inhibitors (e.g., phenelzine): may cause hypertensive crisis when combined. - Antipsychotics with dopamine antagonism (e.g., haloperidol): can diminish therapeutic effect and worsen Parkinsonism. - Antiemetics that block dopamine receptors (e.g., metoclopramide): may reduce levodopa absorption and increase side effects.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure lowering effect may cause symptomatic hypotension. - SSRIs and SNRIs: may increase risk of serotonin syndrome when combined with MAO‑B inhibition. - Iron or calcium supplements: can impair levodopa absorption; separate administration by at least two hours.